Lista de obras -

A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.

artículo científico publicado en 2014

Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories

artículo científico publicado en 2017

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis

artículo científico publicado en 2017

Comparison of JAK2(V617F) -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology

artículo científico publicado en 2017

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a lar

artículo científico publicado en 2018

Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients

scholarly article by Francesca Palandri et al published November 2018 in Leukemia Research

Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study

artículo científico publicado en 2017

Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients

artículo científico publicado en 2018

Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib

scientific article published on 07 June 2019

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib

scientific article published on 04 December 2018

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

artículo científico publicado en 2019

RISK FACTORS FOR PROGRESSION TO BLAST PHASE AND OUTCOME IN 589 PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB: REAL WORLD DATA

scientific article published on 09 April 2020

Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients

artículo científico publicado en 2016

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

artículo científico publicado en 2021

Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients

artículo científico publicado en 2018

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

scientific article published on 29 May 2019

Second cancers in MPN: Survival analysis from an international study

artículo científico publicado en 2019

Second primary malignancy in myelofibrosis patients treated with ruxolitinib

artículo científico publicado en 2020

Lista de obras de

A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera.

Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories

Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis

Comparison of JAK2(V617F) -positive essential thrombocythaemia and early primary myelofibrosis: The impact of mutation burden and histology

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a lar

Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients

Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study

Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients

Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib

Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib

Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis

RISK FACTORS FOR PROGRESSION TO BLAST PHASE AND OUTCOME IN 589 PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB: REAL WORLD DATA

Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients

Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis

Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients

Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

Second cancers in MPN: Survival analysis from an international study

Second primary malignancy in myelofibrosis patients treated with ruxolitinib